Poxel S.A. hopes imeglimin will become physicians' go-to oral therapy to combine with metformin in diabetes. Clinical data show it improves the activity of two affected organs, may be safer than targeted oral antidiabetics and has a unique mechanism of action that could provide efficacy benefits.

Three of the organ-specific defects in diabetes are excess glucose production by the liver, impaired glucose uptake in muscle and insufficient insulin secretion from the pancreas.